Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Lung Neoplasms 4 Neuroma, Acoustic 1 Neurofibromatosis 2 1 NSCLC 1 Meningioma 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Ependymoma 1 ALK-positive Advanced NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ALK-positive Advanced NSCLC × brigatinib × 1 year × Clear all

NCT03535740 2025-07-31

ALTA-2

Takeda

Phase 2 Completed

103 enrolled 23 charts

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡